Table 2 The distribution of healthcare service utilization by year.
2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | RR (crude) | RR (adjusted) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Outpatient visits | 2.39 (2.20) | 2.48 (2.24) | 2.75 (2.36) | 3.08 (3.56) | 2.97 (2.91) | 2.89 (2.91) | 2.95 (3.71) | 2.86 (2.96) | 2.97 (2.38) | 2.82 (2.33) | 1.01 (1.01 to 1.02)*** | 1.01 (1.01 to 1.02)*** |
Admission rate | 15.6 | 17.7 | 18.0 | 14.1 | 15.9 | 14.7 | 17.1 | 13.1 | 13.6 | 12.7 | 0.97 (0.95 to 0.99)** | 0.97 (0.95 to 0.99)** |
Surgery rate | 16.3 | 18.2 | 19.4 | 16.1 | 17.7 | 16.1 | 17.6 | 13.8 | 14.0 | 12.7 | 0.97 (0.95 to 0.98)*** | 0.97 (0.95 to 0.98)*** |
Laparoscopy | 9.3 | 11.1 | 11.1 | 10.8 | 15.3 | 14.0 | 15.4 | 12.0 | 11.9 | 10.1 | 1.01 (0.99 to 1.03) | 1.01 (0.99 to 1.03) |
Surgery type | ||||||||||||
Extirpation of benign adnexal tumor | 9.3 | 8.9 | 10.0 | 10.0 | 11.4 | 9.6 | 11.4 | 9.4 | 9.4 | 8.4 | 0.99 (0.97 to 1.02) | 0.99 (0.97 to 1.02) |
Pelviscopic fulguration | 1.2 | 1.4 | 0.8 | 1.5 | 2.0 | 1.8 | 1.5 | 1.2 | 1.1 | 0.5 | 0.96 (0.89 to 1.03) | 0.96 (0.90 to 1.03) |
Prescription rate | ||||||||||||
Hormone therapy | 41.4 | 38.0 | 35.5 | 40.0 | 45.9 | 45.8 | 46.0 | 46.7 | 50.4 | 50.0 | 1.03 (1.02 to 1.05)*** | 1.03 (1.02 to 1.05)*** |
Estrogen or progesterone | 15.9 | 14.2 | 12.0 | 23.2 | 34.2 | 34.0 | 35.5 | 36.7 | 40.2 | 41.4 | 1.13 (1.11 to 1.14)*** | 1.13 (1.11 to 1.14)*** |
Dienogest | 0.0 | 0.0 | 0.0 | 12.1 | 27.6 | 27.0 | 28.7 | 30.8 | 34.8 | 36.0 | 1.27 (1.25 to 1.30)*** | 1.28 (1.25 to 1.30)*** |
Tibolone | 4.3 | 4.4 | 3.8 | 4.4 | 3.5 | 2.8 | 2.3 | 2.5 | 2.8 | 2.6 | 0.93 (0.89 to 0.97)*** | 0.93 (0.89 to 0.97)*** |
GnRH analogues | 33.6 | 31.5 | 31.3 | 26.7 | 20.3 | 19.1 | 17.2 | 16.3 | 18.3 | 16.4 | 0.91 (0.90 to 0.93)*** | 0.91 (0.90 to 0.93)*** |
Leuprorelin | 23.1 | 22.5 | 23.8 | 20.3 | 14.5 | 15.3 | 13.7 | 13.6 | 15.2 | 14.3 | 0.94 (0.92 to 0.95)*** | 0.94 (0.92 to 0.95)*** |
Goserelin | 5.8 | 5.5 | 5.7 | 4.4 | 3.1 | 2.2 | 1.5 | 1.5 | 2.0 | 0.9 | 0.82 (0.78 to 0.86)*** | 0.82 (0.78 to 0.86)*** |
NSAIDs | 26.6 | 28.5 | 26.9 | 17.3 | 13.4 | 10.7 | 12.5 | 11.1 | 10.7 | 12.8 | 0.89 (0.87 to 0.91)*** | 0.89 (0.87 to 0.91)*** |
Prescription days | ||||||||||||
Hormone therapy | 24.1 (52.1) | 29.2 (59.2) | 23.9 (50.6) | 47.5 (84.4) | 76.9 (111.4) | 63.1 (97.4) | 71.4 (117.2) | 75.7 (113) | 78.4 (119) | 73.8 (112.2) | 1.11 (1.11 to 1.11)*** | 1.11 (1.11 to 1.12)*** |
Estrogen or progesterone | 52 (72.1) | 66.6 (79.5) | 62.5 (71.2) | 77.7 (99.3) | 100.7 (119.3) | 83 (105.4) | 90.6 (126.9) | 91.6 (118.7) | 95.6 (126.5) | 87.6 (118.2) | 1.03 (1.03 to 1.04)*** | 1.04 (1.03 to 1.04)*** |
Dienogest | – | – | – | 77.1 (106.6) | 106.1 (124.2) | 81.7 (107.5) | 93 (129.1) | 93.4 (118.3) | 92.5 (123.6) | 86 (117.9) | 0.99 (0.99 to 0.99)*** | 0.99 (0.99 to 0.99)*** |
Tibolone | 53.3 (41.2) | 88.9 (76.2) | 87.1 (70) | 116.1 (97.3) | 85.5 (79.5) | 98.3 (99.8) | 92 (85.3) | 102.3 (102.7) | 108.4 (102.7) | 100.5 (102) | 1.04 (1.03 to 1.04)*** | 1.04 (1.04 to 1.04)*** |
GnRH analogues | 3 (1.7) | 3.1 (1.7) | 3.1 (1.8) | 3.4 (1.7) | 3.1 (1.7) | 3.1 (1.8) | 3.1 (1.6) | 2.9 (1.5) | 3.1 (1.9) | 3 (1.7) | 1.00 (0.99 to 1.01) | 1.00 (0.99 to 1.01) |
Leuprorelin | 3 (1.7) | 2.9 (1.7) | 3.1 (1.8) | 3.4 (1.7) | 3.1 (1.7) | 3.1 (1.9) | 3 (1.6) | 2.8 (1.5) | 3 (1.6) | 3 (1.7) | 1.00 (0.99 to 1.01) | 1.00 (0.99 to 1.01) |
Goserelin | 2.4 (1.7) | 3.3 (1.7) | 2.7 (1.7) | 3.2 (1.9) | 3.2 (1.5) | 2.8 (1.5) | 3.4 (1.6) | 3.4 (2) | 2.9 (1.9) | 3.4 (1.6) | 1.02 (0.99 to 1.05) | 1.02 (0.99 to 1.05) |
NSAIDs | 11.2 (17.6) | 15 (30.9) | 9.6 (10.6) | 13.9 (38) | 9.4 (11.8) | 10.6 (15) | 11.1 (18.9) | 8.9 (12.3) | 9.9 (13.3) | 12.6 (23.4) | 0.98 (0.98 to 0.99)*** | 0.98 (0.98 to 0.99)*** |
